Koninklijke Philips (NYSE:PHG) Raised to Buy at Wall Street Zen

Koninklijke Philips (NYSE:PHG - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

Other analysts have also issued research reports about the company. Sanford C. Bernstein raised Koninklijke Philips from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 18th. BNP Paribas raised Koninklijke Philips from a "neutral" rating to an "outperform" rating in a research note on Tuesday, February 25th. Finally, UBS Group raised Koninklijke Philips from a "neutral" rating to a "buy" rating in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy".

Koninklijke Philips Trading Up 1.5%

Shares of NYSE:PHG traded up $0.36 during midday trading on Friday, reaching $23.84. 1,549,671 shares of the company's stock were exchanged, compared to its average volume of 852,086. The stock has a market cap of $22.40 billion, a price-to-earnings ratio of -28.38, a P/E/G ratio of 0.82 and a beta of 0.76. Koninklijke Philips has a fifty-two week low of $21.48 and a fifty-two week high of $32.91. The firm's 50 day simple moving average is $23.71 and its two-hundred day simple moving average is $25.37. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.23 and a quick ratio of 0.74.

Koninklijke Philips (NYSE:PHG - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The technology company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.13. The business had revenue of $4.31 billion during the quarter, compared to analysts' expectations of $4.10 billion. Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.85%. The business's revenue for the quarter was down 1.0% on a year-over-year basis. During the same period last year, the business earned $0.21 earnings per share. As a group, sell-side analysts forecast that Koninklijke Philips will post 1.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Colonial Trust Co SC lifted its holdings in Koninklijke Philips by 724.0% during the 4th quarter. Colonial Trust Co SC now owns 1,409 shares of the technology company's stock worth $36,000 after buying an additional 1,238 shares in the last quarter. Bessemer Group Inc. increased its position in shares of Koninklijke Philips by 2,935.4% during the first quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company's stock worth $51,000 after acquiring an additional 1,908 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Koninklijke Philips by 37.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,150 shares of the technology company's stock valued at $54,000 after acquiring an additional 582 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in Koninklijke Philips in the fourth quarter valued at $55,000. Finally, Millstone Evans Group LLC purchased a new position in Koninklijke Philips in the fourth quarter valued at $60,000. Institutional investors and hedge funds own 13.67% of the company's stock.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.